

REMARKS

Claims 1 to 3, 5 to 21, 23 to 29, 31 to 33, 35 to 39, 41 to 57, 59 to 65, 67 to 69, 71 to 73, and 79 to 81, as amended, appear in this application for the Examiner's review and consideration. Claims 4, 22, 30, 34, 40, 58, 66, 70, 74 to 78, and 82 to 88 have been canceled without prejudice to Applicants' right to file one or more divisional or continuation applications directed to the subject matter of those claims. Claims 17 to 19, 23 to 27, 53 to 55, 59 to 63, and 79 to 81 have been withdrawn from consideration as being drawn to a non-elected species. The amendments are fully supported by the specification and claims as originally filed. Therefore, there is no issue of new matter.

Applicants acknowledge with appreciation the indication of allowable subject matter in claims 9 to 14 and 45 to 50, and submit that the other pending claims under consideration are also in condition for allowance for the reasons set forth below.

Claims 30, 34, 66, and 70 were rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the enablement requirement for the reasons set forth on pages 3 and 4 of the Office Action. In response, Applicants submit that those claims have been canceled, mooting the rejection. Therefore, it is respectfully requested that the Examiner withdraw the rejection of claims 30, 34, 66, and 70 under 35 U.S.C. §112, first paragraph.

Claims 1 to 8, 15, 16, 20 to 22, 37 to 52, 56 to 58, 64 to 78, and 82 to 88 were rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite for the reasons set forth on pages 4 and 5 of the Office Action.

In response, Applicants submit that the definition of the R groups in the compounds of the invention has been changed in the claims to recite that each of R₈, R₁₀, and R₁₂ to R₁₄ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkylaryl, CN, CF₃, CO₂R, C(O)R, NR₂, NO₂, OR, halo, aryl, heteroaryl, substituted aryl, substituted heteroaryl, or a heterocyclic group, wherein each R is independently selected from H, alkyl, alkylaryl, aryl, and heteroaryl. The claims have been further amended to recite that the 4- to 7-member cyclic group may be optionally substituted with a substituent independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkylaryl, CN, CF₃, CO₂R, C(O)R, NR₂, NO₂, OR, halo, aryl, heteroaryl, substituted aryl, substituted heteroaryl, or a heterocyclic group, wherein each R is independently selected from H, alkyl, alkylaryl, aryl, and heteroaryl. Therefore, the R variables are fully defined.

With regard to claims 15, 16, 51, 52, 77, and 78, claims 15 and 51 have been amended to recite that at least one of R₈, R₁₀, R₁₁ to R₁₄, and a substituent of (C-N) is independently selected from substituted or unsubstituted phenyl, naphthyl, or pyridyl, and claims 16 and 52 have been amended to recite that at least one of R₈, R₁₀, R₁₁ to R₁₄, and a substituent of (C-N) is phenyl. Claims 77 and 78 have been canceled, mooting the rejection of those claims. One of ordinary skill in the art will understand that the amended claims require a compound having at least one substituent group.

With regard to claims 21 and 57, those claims have been amended to recite that at least one ligand is a phosphorescent emissive ligand in the compound at room temperature, and at least one ligand is not a phosphorescent emissive ligand in the compound at room temperature. Therefore, one of ordinary skill in the art will understand that, when present in the claimed compound, at least one ligand is an emissive phosphorescent ligand at room temperature, and at least one ligand is not a phosphorescent emissive ligand at room temperature.


With regard to the recitation of “further” in line 5 of claims 37, 64, 69, and 74, those claims have been amended to delete the recitation of “further.”

With regard to the recitation of “first ligand” in claims 84 and 85, those claims have been canceled, mooting the rejection of those claims.


Therefore, the claims particularly point out and distinctly claim the subject matter Applicants regard as the invention, and, thus, are not indefinite. Accordingly, it is respectfully requested that the Examiner withdraw the rejection of claims 1 to 8, 15, 16, 20 to 22, 37 to 52, 56 to 58, 64 to 78, and 82 to 88 under 35 U.S.C. §112, second paragraph.

Claims 1 to 3, 15, 16, 20, 21, 37 to 39, 51, 52, 56, 57, 74, 77, 78, 82, 84, and 86 to 88 were rejected under 35 U.S.C. §102(b), as allegedly being anticipated by U.S. Patent Application Publication No. 2001/0019782 A1 to Igarashi et al. (“Igarashi”) for the reasons set forth on pages 5 to 7 of the Office Action, and claims 15, 16, 28, 29, 31 to 33, 35, 36, 51, 52, 64, 65, 67 to 69, 71 to 73, 77, 78, and 85 were rejected under 35 U.S.C. §103(a) as being unpatentable for the reasons set forth on pages 8 and 9 of the Office Action.

In response, Applicants submit that claim 1 has been amended to recite a compound, having the structure:



and that claim 37 has been amended to recite an organic light emitting device, comprising an emissive layer, comprising a compound having the structure



Igarashi does not disclose or suggest the presently claimed compound. Therefore, Igarashi does not disclose or suggest the presently claimed invention, as recited in claims 1 and 37. Moreover, as each of the rejected dependent claims depends from either claim 1 or claim 37, Igarashi does not disclose or suggest the invention recited in any of those claims.

Therefore, as Igarashi does not disclose or suggest the presently claimed invention, the claims are not anticipated by or obvious over Igarashi. Accordingly, it is respectfully requested that the Examiner withdraw the rejections of the claims under 35 U.S.C. §§102(b) and 103(a) over Igarashi.

Claims 74, 82, 83, and 86 were rejected under 35 U.S.C. §102(a) and 102(e), as allegedly being anticipated by U.S. Patent Application Publication No. 2002/0182441 to Lamansky et al. (“Lamansky”) for the reasons set forth on pages 7 and 8 of the Office Action, and claims 75 and 76 were rejected under 35 U.S.C. §103(a), as allegedly being unpatentable over Lamansky for the reasons set forth on page 10 of the Office Action.

In response, Applicants submit that claims 74, 75, 76, 82, 83, and 86 have been canceled without prejudice, mooting the rejections of those claims. Therefore, it is respectfully requested that the Examiner withdraw the rejections of claims 74, 75, 76, 82, 83, and 86 under 35 U.S.C. §§ 102(a), 102(e), and 103(a) over Lamansky.

With regard to the miscellaneous matters set forth on page 10, Applicants submit that the suggested changes have been made.

With regard to the reference to the Dedeian article on page 11 of the Office Action, Applicants respectfully submit that the article is dated 2005, and, thus, was published after the filing date of the present application. Therefore, Applicants wish to make it of record that the referenced article may possibly disclose Applicants' elected species, but the article cannot anticipate the elected species.

Applicants thus submit that the entire application is now in condition for allowance, an early notice of which would be appreciated. Should the Examiner not agree with Applicants' position, a personal or telephonic interview is respectfully requested to discuss any remaining issues prior to the issuance of a further Office Action, and to expedite the allowance of the application.

No fee is believed to be due for the filing of this Amendment. Should any fees be due, however, please charge such fees to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON

Dated: January 17, 2007

By: Alan P. Force
Alan P. Force
Reg. No. 39,673
One Broadway
New York, NY 10004
(212) 425-7200